"...and perhaps the trial should never have been blinded!!!!,,,,maybe our bear can chime in on the spectacular reasoning behind a blinded trial.....especially when the company has no money to extend the trial for any reasons!"

Easy. One wants to eliminate the possibility of intentional or unintentional bias. Blinded/masked trials are the norm. In the case of BETonMACE, all patients, investigators, care providers, clinical steering committee and Resverlogix remain blinded to the trial data. It keeps everyone honest and maximizes the validity of the results.

"I dont expect any movement in share price until the final BoM results are in,,,,,,,,,,,,top line results may not even cut it!!,,its the market we exist in, coupled with what we have at the moment driving us.....jmo"

So to paraphrase....Narmac has stated the opinion that even if Resverlogix announces top-line results that a first-in-class novel drug, apabetalone, nails its primary outcome in BETonMACE of achieving a statistically significant reduction in 3-point MACE in diabetic, low-HDL, high-CVD risk patients treated with apabetalone compared to placebo, that the share price won't budge. LOL. SMH. I'll take that bet.